Sign in Subscribe
Economic development

Advances in Radiopharmaceutical Research for Cancer, CNS Diseases, and Cardiovascular Diseases

Strategic Insights

— 1 min read

Beijing researchers have highlighted the importance of radiopharmaceuticals in the early diagnosis and treatment of major diseases such as cancer, central nervous system (CNS) diseases, and cardiovascular diseases. With the Chinese government's support through policies like the "Radiopharmaceutical Industrial Development Plan" in 2021, the field has seen significant progress. A recent study by researchers at Beijing Normal University, led by Hua-bei ZHANG and Yu FANG, reviews the latest advancements in radiopharmaceutical research, providing insights into the development trends and future directions in China.

Key Takeaways:

  • The research focused on radiopharmaceuticals targeting cancer, CNS diseases, and cardiovascular diseases, with a special emphasis on cancer-related research.
  • The study introduced the latest progress in radiopharmaceutical research, including targeting popular targets like prostate surface membrane antigen (PSMA) and fibroblast activation protein (FAP), as well as cancer-specific biomarkers and dual-target radiopharmaceuticals.
  • The researchers highlighted the importance of emerging technologies like artificial intelligence drug discovery (AIDD), computer-aided drug design (CADD), and DNA-encoded compound libraries (DEL) in the development of radiopharmaceuticals.
  • The study recommended strengthening basic research on new targets and mechanisms, as well as combining radioactive drugs with other treatment or diagnostic methods for major diseases.
  • By addressing the homogeneity problem in radiopharmaceutical development, the research aims to accelerate the development of these drugs.

Statistics:

  • 2021: The Chinese government issued the "Radiopharmaceutical Industrial Development Plan" to promote the industrial development of radiopharmaceuticals in China.
  • 47(4):456-482: The volume and page numbers of the journal article "Progress and Prospects of Research and Development of Radio- pharmaceuticals in China" published in He Huaxue Yu Fangshe Huaxue.
  • 2025: The year in which the research was conducted and published.
  • 10.7538/hhx.2025.47.04.0456: The digital object identifier (DOI) for the free version of the journal article.

Sources:

  • NewsRx. Reports Outline Cancer Study Results from Beijing Normal University (Progress and Prospects of Research and Development ofRadiopharmaceuticals in China). Health & Medicine Week. September 12, 2025; p 4377.
  • Zhang, H., Fang, Y. (2025). Progress and Prospects of Research and Development of Radio-pharmaceuticals in China. He Huaxue Yu Fangshe Huaxue, 2025,47(4):456-482.

Read more